Monoclonal Antibody Therapies: Streamlining Development, Production, Costs

Speakers

Keith Canada, PhD

Boehringer Ingelheim
e-mail

Keith Canada is a senior scientist in the Biologics and Biomolecular Sciences division of Boehringer Ingelheim Pharmaceuticals.

Louis M. Weiner, MD

Fox Chase Cancer Center
e-mail | web site | publications

Louis Weiner is chairman of the Department of Medical Oncology and vice president of translational research at the Fox Chase Cancer Center. His work focuses on conducting translational research employing targeted therapy of cancer by antibody-based proteins. He serves on numerous National Cancer Institute review panels, including the Translational Research Working Group (TRWG), the Cancer Immunopathology and Immunotherapy (CII) study section, and the Rapid Access to Intervention Development (RAID) program oversight committee. Weiner completed his medical education at the Mount Sinai School of Medicine and has held fellowships at the New England Medical Center Hospital at Tufts University School of Medicine.

Joseph P. Balthasar, PhD

University of Buffalo
e-mail | web site | publications

Joseph Balthasar is an associate professor of pharmaceutical sciences at the University of Buffalo. He completed his PhD in pharmaceutics at the State University of New York at Buffalo. His research focuses on the application of pharmacokinetic and pharmacodynamic analyses to design new treatments for ovarian cancer and for autoimmune diseases.

E. Sally Ward, PhD

University of Texas Southwestern Medical Center
e-mail | web site | publications

Sally Ward is the Paul and Betty Meek–FINA Professor in Molecular Immunology at the University of Texas Southwestern Medical Center. Her laboratory's primary interest is in investigating how FcRn functions as an IgG transporter to regulate IgG levels throughout the body. She is also working to develop engineered antibodies that are altered in their binding properties for FcRn and, as such, can modulate FcRn function. Ward completed her undergraduate and doctoral degrees at the University of Cambridge and held two fellowships there before migrating to the United States.

T. Shantha Raju, PhD

Cenotcor
e-mail | publications

Shantha Raju is a research fellow at Centocor R&D, a biotechnology company owned by Johnson & Johnson.

Kevin Bailey, PhD

Regeneron Pharmaceuticals
e-mail | publications

Kevin Bailey is vice president of preclinical manufacturing and process development at Regeneron Pharmaceuticals.

Gordon Moore, PhD

Centocor
e-mail

Gordon Moore is senior director of cell biology at Centocor Pharmaceutical Development.

Patrick Garidel, PhD

Boehringer Ingelheim
e-mail | publications

Patrical Garidel is head of pharmaceutical basic development at Boehringer Ingelheim Pharma GmbH & Co. KG, based in Biberach an der Riss, Germany.

Paul Andrews, PhD

Patrys Limited
e-mail | publications

Paul Andrews is vice president of research and development at Patrys, Ltd. His duties include designing, implementing, and managing nonclinical safety assessment programs to support clinical development of Patrys' IgM monoclonal antibodies; preparing regulatory submissions; participating in IND-candidate selection; formulating early clinical development plans; and participating in partnering efforts. Prior to joining Patrys, he was assistant vice president of toxicology at ImClone Systems, where he supervised the nonclinical development of monoclonal antibody therapeutics and the nonclinical bioanalytical laboratory. He has also held positions at Aton Pharma and Cato Research, and worked as pharmacology team leader at the U.S. Food and Drug Administration's Division of Oncology Drug Products. He earned his PhD in medicinal chemistry from the University of Maryland at Baltimore.